No use of Chinese patent medicine not in the national base catalogue!

In addition to these 268 basic drug varieties, the rest of the domestic Chinese patent medicines are basically rejected by this top three hospital ▍ recently, some people familiar with the situation provided a provisional regulation on the clinical use management of Chinese patent medicine (hereinafter referred to as the "regulation") of provincial top three hospitals to cypress blue The detailed rules are as follows: 1 The varieties of oral and external Chinese patent medicines currently in use in our hospital, which belong to the catalogue of national essential medicines (2018 Edition) (hereinafter referred to as the "national basic catalogue"), are all open to use, no longer limited; the varieties of traditional Chinese medicine injections for internal use in the "national basic catalogue" are limited to use in the Department of traditional Chinese medicine and cadre ward according to the provisions of the plan; 2 At present, the varieties of oral and external Chinese patent medicines not included in the national basic catalogue are only used in TCM department and cadre ward, and other departments are suspended The traditional Chinese medicine injections not included in the national basic catalogue are only used by the Department of traditional Chinese medicine and the cadre ward 3 In order to ensure the safety of drug use, the varieties of Chinese patent medicines applied for use by clinical departments must have clear indications Chinese patent medicine varieties marked with "functional indications" without definite indications Except for the Department of traditional Chinese medicine, other departments shall not apply for the use of traditional Chinese medicine; 4 When the cadre health care object is hospitalized in the general ward, the traditional Chinese medicine can be reasonably used according to the needs of the disease; 5 Each clinical department, especially the cadre ward and the traditional Chinese medicine department, should strengthen the management The prescription doctors should strictly follow the diagnosis and treatment specifications, and use the proprietary Chinese medicine according to the functions or indications of the drug instructions, so as to eliminate unreasonable use of drugs This means that the varieties of Chinese patent medicines that are not listed in the national base catalogue will lose most of the market of the provincial top three So, how many varieties of Chinese patent medicine will be affected? On October 25, 2018, the official website of the national health and Health Commission issued the notice on printing and distributing the National Essential Drug Catalogue (2018 Edition) It is understood that the national basic catalogue has increased the number of varieties from 520 to 685 There are 268 varieties of Chinese patent medicines mainly classified according to their functions Therefore, in addition to these 268 basic drug varieties, the rest of the domestic Chinese patent medicines are basically rejected by this top three hospital After all, in addition to the traditional Chinese medicine department, other clinical departments need to apply for and ensure that the varieties of Chinese patent medicine have clear indications before using the corresponding drugs ▍ a number of policies suggest the development of traditional Chinese medicine Although the fist of fee control is always on traditional Chinese medicine, in fact, the state's encouragement of the development of traditional Chinese medicine is a definite direction In China, in order to promote the development of traditional Chinese medicine and promote the development of both Chinese and Western medicine in domestic medicine, industrial development policies began to be issued intensively According to the statistics of Changqing Research Institute of basic industry, from 2009 to March 2018, the state issued 36 policies of traditional Chinese medicine, and put forward policy suggestions to support the development of traditional Chinese medicine at 9 national conferences The strategic planning outline for the development of traditional Chinese medicine (2016-2030) issued in 2016 points out the direction for the development of traditional Chinese medicine industry According to the plan, the scale of traditional Chinese medicine industry will reach 8 trillion yuan in 2030 ▍ although the general direction of how to find the balance of Chinese patent medicine is to encourage, the state has also introduced many restrictive policies, such as the introduction of auxiliary drugs, key monitoring directory, new version of medical insurance directory This is closely related to the problems in the use of proprietary Chinese medicine According to statistics, in the 2017 ADR / event report, there were about 17000 serious ADRs caused by traditional Chinese medicine In addition, in the drug specification of Chinese patent medicine, "adverse reactions are not clear" is a common phenomenon According to the data, researchers from the former State Food and Drug Administration and Beijing University of traditional Chinese Medicine collected 1618 manuals of proprietary Chinese medicine on the market in 2017, 80.2% of which said "adverse reactions are not clear" At the same time, the abuse of Chinese patent medicine is also a problem: after analyzing 200 prescriptions of Chinese patent medicine in four general hospitals in Henan Province, some scholars found that 40.5% of these prescriptions were used improperly, 30.5% were prescribed beyond the range, and 23.5% were not consistent with the diagnosis In this context, many medical institutions in order to control medical costs, often in the Chinese patent medicine There are many limitations in the admission, clinical use and drug proportion assessment of Chinese patent medicine For example, some hospitals clearly stipulate that "traditional Chinese medicine preparations shall not be accepted" in the catalogue of drugs for record and purchase, and many hospitals explicitly require doctors to restrict the use of traditional Chinese medicine In the process of encouragement and restriction, how can Chinese patent medicine find its own way of development? Huatai Securities believes that the guiding logic behind the policy is to encourage the return of traditional Chinese medicine usage On the one hand, traditional Chinese medicine injections face pressure of shuffling after rough growth In the last round of modernization of traditional Chinese medicine, traditional Chinese medicine injection swept the market and ranked the top in sales However, due to the questionable safety and the pressure of medical insurance fee control, the state has restricted the injection of traditional Chinese medicine through auxiliary medication, key monitoring, medical insurance catalog setting and other ways Only when the industry has structural changes, the injection with accurate curative effect, accurate indications and higher safety can be retained in this round of shuffling On the other hand, the current policy of the state on traditional Chinese medicine encourages traditional usage, and the encouragement of oral varieties is the change brought about by the restrictions on traditional Chinese medicine injections set by the medical insurance catalog The encouragement of traditional Chinese medicine Pieces stems from the policies of not canceling 25% of drug addition, not counting into the proportion of drugs in public hospitals, not including in the centralized purchase of drugs, etc